PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)
   Google Scholar   
Citation:
J Clin Oncol vol 37 (suppl) abstr TPS4596
Meeting Instance:
ASCO 2019
Year:
2019
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
No-Endpoint
Analysis:
Trial-Description-Only
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epreprint
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
Health Outcomes    
Pharmas:
 
Grants:
UG1CA189823  
Corr. Author:
 
Authors:
                         
Networks:
KANSAS, LAPS-MA036, LAPS-NC010, LAPS-NY016, LAPS-TX011, LAPS-WI020, OH027   
Study
Alliance-A031704
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: